Skip to main content
SpringerLink
Log in
Book cover

Clinical Ophthalmic Oncology pp 119–127Cite as

Retinoblastoma: Intravenous Chemotherapy

  • Chapter
  • First Online:

Abstract

The management of patients with intraocular retinoblastoma has changed dramatically in the past 20 years with the introduction of primary systemic chemotherapy. Before 1990, systemic chemotherapy had been used to treat patients with extraocular disease, with less than optimal results. In the early 1990s, several investigators from North America and the United Kingdom began using chemotherapy agents that were effective against central nervous system tumors, to treat intraocular retinoblastoma. The rationale was to achieve decrease in intraocular tumor volume with systemic chemotherapy (chemoreduction) so as to allow better tumor kill with local treatment using photocoagulation and cryotherapy. Further, it was hoped that the use of chemotherapy would help to eliminate the need for external beam radiation therapy (EBRT) in this patient population susceptible to second malignancy.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. White L. Chemotherapy in retinoblastoma: current status and future directions. Am J Pediatr Hematol Oncol. 1991;13(2):189–201.

    Article  PubMed  CAS  Google Scholar 

  2. Shields CL, De Potter P. Chemoreduction in the initial management of intraocular retinoblastoma. Arch Ophthalmol. 1996;114(11):1330–8.

    Article  PubMed  CAS  Google Scholar 

  3. Murphree AL, Villablanca JG, Deegan 3rd WF, et al. Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol. 1996;114(11):1348–56.

    Article  PubMed  CAS  Google Scholar 

  4. Kingston JE, Hungerford JL. Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma. Arch Ophthalmol. 1996;114(11):1339–43.

    Article  PubMed  CAS  Google Scholar 

  5. Kleinerman RA, Tucker MA, Tarone RE, et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J Clin Oncol. 2005;23(10):2272–9.

    Article  PubMed  Google Scholar 

  6. Marees T, Moll AC, Imhof SM, et al. Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. J Natl Cancer Inst. 2008;100(24):1771–9.

    Article  PubMed  Google Scholar 

  7. Rodriguez-Galindo C, Wilson MW, Haik BG, et al. Treatment of intraocular retinoblastoma with vincristine and carboplatin. J Clin Oncol. 2003;21(10):2019–25.

    Article  PubMed  CAS  Google Scholar 

  8. Gallie BL, Budning A, DeBoer G, et al. Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophthalmol. 1996;114(11):1321–8.

    Article  PubMed  CAS  Google Scholar 

  9. Dunkel IJ, Lee TC, Shi W, et al. A phase II trial of carboplatin for intraocular retinoblastoma. Pediatr Blood Cancer. 2007;49(5):643–8.

    Article  PubMed  Google Scholar 

  10. Qaddoumi I, Billups CA, Tagen M, et al. Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity. Cancer. 2012;118(22):5663–70.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  11. Chantada G, Fandiño A, Casak S, et al. Treatment of overt extraocular retinoblastoma. Med Pediatr Oncol. 2003;40(3):158–61.

    Article  PubMed  Google Scholar 

  12. Antoneli CBG, Steinhorst F, De Cássia Braga Ribeiro K, et al. Extraocular retinoblastoma: a 13-year experience. Cancer. 2003;98(6):1292–8.

    Article  PubMed  Google Scholar 

  13. Linn Murphree A. Intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin North Am. 2005;18(1):41–53, viii.

    Article  PubMed  CAS  Google Scholar 

  14. Shields CL, Mashayekhi A, Au AK, et al. The International Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology. 2006;113(12):2276–80.

    Article  PubMed  Google Scholar 

  15. Friedman DL, Himelstein B, Shields CL, et al. Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. J Clin Oncol. 2000;18(1):12–7.

    PubMed  CAS  Google Scholar 

  16. Shields CL, Honavar SG, Meadows AT, et al. Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation. Am J Ophthalmol. 2002;133(5):657–64.

    Article  PubMed  Google Scholar 

  17. Berry JL, Jubran R, Kim JW, et al. Long-term outcomes of Group D eyes in bilateral retinoblastoma patients treated with chemoreduction and low-dose IMRT salvage. Pediatr Blood Cancer. 2012. doi:10.1002/pbc.24303.

    PubMed  Google Scholar 

  18. Abramson DH, Frank CM, Dunkel IJ. A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma. Ophthalmology. 1999;106(10):1947–50.

    Article  PubMed  CAS  Google Scholar 

  19. Mulvihill A, Budning A, Jay V, et al. Ocular motility changes after subtenon carboplatin chemotherapy for retinoblastoma. Arch Ophthalmol. 2003;121(8):1120–4.

    Article  PubMed  CAS  Google Scholar 

  20. Uusitalo MS, Van Quill KR, Scott IU, et al. Evaluation of chemoprophylaxis in patients with unilateral retinoblastoma with high-risk features on histopathologic examination. Arch Ophthalmol. 2001;119(1):41–8.

    PubMed  CAS  Google Scholar 

  21. Chantada GL, Dunkel IJ, De Dávila MTG, Abramson DH. Retinoblastoma patients with high risk ocular pathological features: who needs adjuvant therapy? Br J Ophthalmol. 2004;88(8):1069–73.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  22. Honavar SG, Singh AD, Shields CL, et al. Postenucleation adjuvant therapy in high-risk retinoblastoma. Arch Ophthalmol. 2002;120(7):923–31.

    Article  PubMed  Google Scholar 

  23. Eagle Jr RC. High-risk features and tumor differentiation in retinoblastoma: a retrospective histopathologic study. Arch Pathol Lab Med. 2009;133(8):1203–9.

    PubMed  Google Scholar 

  24. Kaliki S, Shields CL, Shah SU, et al. Postenucleation adjuvant chemotherapy with vincristine, etoposide, and carboplatin for the treatment of high-risk retinoblastoma. Arch Ophthalmol. 2011;129(11):1422–7.

    Article  PubMed  CAS  Google Scholar 

  25. Chintagumpala M, Langholz B, Eagle RC Jr, et al. A large prospective trial of children with unilateral retinoblastoma with and without histopathologic high-risk features and the role of adjuvant chemotherapy: a Children’s Oncology Group (COG) study. J Clin Oncol. 2012;30(suppl; abstr 9515).

    Google Scholar 

  26. Jubran RF, Erdreich-Epstein A, Butturini A, Murphree AL, Villablanca JG. Approaches to treatment for extraocular retinoblastoma: Children’s Hospital Los Angeles experience. J Pediatr Hematol Oncol. 2004;26(1):31–4.

    Article  PubMed  Google Scholar 

  27. Chantada G, Doz F, Antoneli CBG, et al. A proposal for an international retinoblastoma staging system. Pediatr Blood Cancer. 2006;47(6):801–5.

    Article  PubMed  Google Scholar 

  28. Chantada GL, Guitter MR, Fandiño AC, et al. Treatment results in patients with retinoblastoma and invasion to the cut end of the optic nerve. Pediatr Blood Cancer. 2009;52(2):218–22.

    Article  PubMed  Google Scholar 

  29. Namouni F, Doz F, Tanguy ML, et al. High-dose chemotherapy with carboplatin, etoposide and cyclophosphamide followed by a haematopoietic stem cell rescue in patients with high-risk retinoblastoma: a SFOP and SFGM study. Eur J Cancer. 1997;33(14):2368–75.

    Article  PubMed  CAS  Google Scholar 

  30. Dunkel IJ, Aledo A, Kernan NA, et al. Successful treatment of metastatic retinoblastoma. Cancer. 2000;89(10):2117–21.

    Article  PubMed  CAS  Google Scholar 

  31. Matsubara H, Makimoto A, Higa T, et al. A multidisciplinary treatment strategy that includes high-dose chemotherapy for metastatic retinoblastoma without CNS involvement. Bone Marrow Transplant. 2005;35(8):763–6.

    Article  PubMed  CAS  Google Scholar 

  32. Dunkel IJ, Chan HSL, Jubran R, et al. High-dose chemotherapy with autologous hematopoietic stem cell rescue for stage 4B retinoblastoma. Pediatr Blood Cancer. 2010;55(1):149–52.

    PubMed  Google Scholar 

  33. De Potter P, Shields CL, Shields JA. Clinical variations of trilateral retinoblastoma: a report of 13 cases. J Pediatr Ophthalmol Strabismus. 1994;31(1):26–31.

    PubMed  Google Scholar 

  34. Amoaku WM, Willshaw HE, Parkes SE, Shah KJ, Mann JR. Trilateral retinoblastoma. A report of five patients. Cancer. 1996;78(4):858–63.

    Article  PubMed  CAS  Google Scholar 

  35. Dunkel IJ, Jubran RF, Gururangan S, et al. Trilateral retinoblastoma: potentially curable with intensive chemotherapy. Pediatr Blood Cancer. 2010;54(3):384–7.

    Article  PubMed  Google Scholar 

  36. Blommaert FA, Van Dijk-Knijnenburg HC, Dijt FJ, et al. Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells. Biochemistry. 1995;34(26):8474–80.

    Article  PubMed  CAS  Google Scholar 

  37. Lambert MP, Shields C, Meadows AT. A retrospective review of hearing in children with retinoblastoma treated with carboplatin-based chemotherapy. Pediatr Blood Cancer. 2008;50(2):223–6.

    Article  PubMed  Google Scholar 

  38. Jehanne M, Lumbroso-Le Rouic L, Savignoni A, et al. Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma. Pediatr Blood Cancer. 2009;52(5):637–43.

    Article  PubMed  Google Scholar 

  39. Smith MA, Rubinstein L, Anderson JR, et al. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol. 1999;17(2):569–77.

    PubMed  CAS  Google Scholar 

  40. Correia JJ. Effects of antimitotic agents on tubulin-nucleotide interactions. Pharmacol Ther. 1991;52(2):127–47.

    Article  PubMed  CAS  Google Scholar 

  41. Rizzuti AE, Dunkel IJ, Abramson DH. The adverse events of chemotherapy for retinoblastoma: what are they? Do we know? Arch Ophthalmol. 2008;126(6):862–5.

    Article  PubMed  CAS  Google Scholar 

  42. Leahey A. A cautionary tale: dosing chemotherapy in infants with retinoblastoma. J Clin Oncol. 2012;30(10):1023–4.

    Article  PubMed  CAS  Google Scholar 

  43. Gombos DS, Hungerford J, Abramson DH, et al. Secondary acute myelogenous leukemia in patients with retinoblastoma: is chemotherapy a factor? Ophthalmology. 2007;114(7):1378–83.

    Article  PubMed  Google Scholar 

  44. Nishimura S, Sato T, Ueda H, Ueda K. Acute myeloblastic leukemia as a second malignancy in a patient with hereditary retinoblastoma. J Clin Oncol. 2001;19(21):4182–3.

    PubMed  CAS  Google Scholar 

  45. Turaka K, Shields CL, Meadows AT, Leahey A. Second malignant neoplasms following chemoreduction with carboplatin, etoposide, and vincristine in 245 patients with intraocular retinoblastoma. Pediatr Blood Cancer. 2012;59(1):121–5.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, Children’s Hospital Los Angeles, 4650, Sunset Boulevard, Mailstop 54, Los Angeles, CA, 90027, USA

    Rajkumar Venkatramani MD, MS & Rima Fuad Jubran MD, MPH

  2. Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

    Rajkumar Venkatramani MD, MS & Rima Fuad Jubran MD, MPH

Authors
  1. Rajkumar Venkatramani MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rima Fuad Jubran MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rima Fuad Jubran MD, MPH .

Editor information

Editors and Affiliations

  1. Dept. of Ophthalmic Oncology, Cole Eye Institute Cleveland Clinic Foundation, Cleveland, Ohio, USA

    Arun D. Singh

  2. Department of Ophthalmology, Children's Hospital Los Angeles, Los Angeles, USA

    A. Linn Murphree

  3. University of California, San Francisco, California, USA

    Bertil E. Damato

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Venkatramani, R., Jubran, R.F. (2015). Retinoblastoma: Intravenous Chemotherapy. In: Singh, A., Murphree, A., Damato, B. (eds) Clinical Ophthalmic Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-43451-2_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-43451-2_11

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-43450-5

  • Online ISBN: 978-3-662-43451-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation